|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 2 (July 15), 1999:
pp. 429-433
Whole-Body Positron Emission Tomography Using
18F-Fluorodeoxyglucose for Posttreatment Evaluation in
Hodgkin's Disease and Non-Hodgkin's Lymphoma Has Higher Diagnostic
and Prognostic Value Than Classical Computed Tomography Scan Imaging
G. Jerusalem,
Y. Beguin,
M.F. Fassotte,
F. Najjar,
P. Paulus,
P. Rigo, and
G. Fillet
From the Department of Medicine, Divisions of Oncology-Hematology and
Nuclear Medicine, University of Liège, Liège, Belgium.
A residual mass after treatment of lymphoma is a clinical challenge,
because it may represent vital tumor as well as tissue fibrosis.
Metabolic imaging by 18F-fluorodeoxyglucose
(18F-FDG) positron emission tomography (PET)
offers the advantage of functional tissue characterization that is
largely independent of morphologic criteria. We compared
18F-FDG PET to computed tomography (CT) in the
posttreatment evaluation of 54 patients with Hodgkin's disease (HD) or
intermediate/high-grade non-Hodgkin's lymphoma (NHL). Residual masses
on CT were observed in 13 of 19 patients with HD and 11 of 35 patients
with NHL. Five of 24 patients with residual masses on CT versus 1 of 30 patients without residual masses presented a positive
18F-FDG PET study. Relapse occurred in all 6 patients
(100%) with a positive 18F-FDG PET, 5 of 19 patients
(26%) with residual masses on CT but negative 18F-FDG PET,
and 3 of 29 patients (10%) with negative CT scan and 18F-FDG PET studies (P  .0001). We
observed a higher relapse and death rate in patients with residual
masses at CT compared with patients without residual masses at CT
(progression-free survival at 1 year: 62 ± 10 v
88 ± 7%, P = .0045; overall survival at 1 year: 77 ± 5 v 95 ± 5%, P = .0038). A positive
18F-FDG PET study was even more consistently associated
with poorer survival: compared with patients with a negative
18F-FDG PET study, the 1-year progression-free survival was
0% versus 86% ± 5% (P < .0001) and the 1-year
overall survival was 50% ± 20% versus 92% ± 4% (P < .0001). The detection of vital tumor by 18F-FDG PET after
the end of treatment has a higher predictive value for relapse than
classical CT scan imaging (positive predictive value: 100% v
42%). This could help identify patients requiring intensification
immediately after completion of chemotherapy. However,
18F-FDG PET mainly predicts for early progression but
cannot exclude the presence of minimal residual disease, possibly
leading to a later relapse.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Bodet-Milin, F. Kraeber-Bodere, B. Dupas, F. Morschhauser, T. Gastinne, S. Le Gouill, L. Campion, J.-L. Harousseau, W. A. Wegener, D. M. Goldenberg, et al.
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography
Haematologica,
March 1, 2008;
93(3):
390 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Ulaner, P. M. Colletti, and P. S. Conti
B-Cell Non-Hodgkin Lymphoma: PET/CT Evaluation after 90Y-Ibritumomab Tiuxetan Radioimmunotherapy--Initial Experience
Radiology,
March 1, 2008;
246(3):
895 - 902.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sasaki, N. Shikama, K. Koiwai, and M. Kadoya
Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment
Jpn. J. Clin. Oncol.,
January 1, 2008;
38(1):
43 - 48.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Juweid
18F-FDG PET as a Routine Test for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: Where Is the Evidence?
J. Nucl. Med.,
January 1, 2008;
49(1):
9 - 12.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Terasawa, T. Nihashi, T. Hotta, and H. Nagai
18F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review
J. Nucl. Med.,
January 1, 2008;
49(1):
13 - 21.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tatsumi, J. H. Miller, and R. L. Wahl
18F-FDG PET/CT in Evaluating Non-CNS Pediatric Malignancies
J. Nucl. Med.,
December 1, 2007;
48(12):
1923 - 1931.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Schwarz, B. A. Siegel, F. Dehdashti, and P. W. Grigsby
Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma
JAMA,
November 21, 2007;
298(19):
2289 - 2295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Seam, M. E. Juweid, and B. D. Cheson
The role of FDG-PET scans in patients with lymphoma
Blood,
November 15, 2007;
110(10):
3507 - 3516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kako, K. Izutsu, Y. Ota, Y. Minatani, M. Sugaya, T. Momose, K. Ohtomo, Y. Kanda, S. Chiba, T. Motokura, et al.
FDG-PET in T-cell and NK-cell neoplasms
Ann. Onc.,
October 1, 2007;
18(10):
1685 - 1690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lin, E. Itti, C. Haioun, Y. Petegnief, A. Luciani, J. Dupuis, G. Paone, J.-N. Talbot, A. Rahmouni, and M. Meignan
Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis
J. Nucl. Med.,
October 1, 2007;
48(10):
1626 - 1632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Advani, L. Maeda, P. Lavori, A. Quon, R. Hoppe, S. Breslin, S. A. Rosenberg, and S. J. Horning
Impact of Positive Positron Emission Tomography on Prediction of Freedom From Progression After Stanford V Chemotherapy in Hodgkin's Disease
J. Clin. Oncol.,
September 1, 2007;
25(25):
3902 - 3907.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. G. Schaefer, C. Taverna, K. Strobel, C. Wastl, M. Kurrer, and T. F. Hany
Hodgkin Disease: Diagnostic Value of FDG PET/CT after First-Line Therapy--Is Biopsy of FDG-avid Lesions Still Needed?
Radiology,
July 1, 2007;
244(1):
257 - 262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Herrmann, H. A. Wieder, A. K. Buck, M. Schoffel, B.-J. Krause, F. Fend, T. Schuster, C. Meyer zum Buschenfelde, H.-J. Wester, J. Duyster, et al.
Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma
Clin. Cancer Res.,
June 15, 2007;
13(12):
3552 - 3558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Zinzani, M. Tani, R. Trisolini, S. Fanti, V. Stefoni, M. Alifano, P. Castellucci, G. Musuraca, G. Dalpiaz, L. Alinari, et al.
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma
Haematologica,
June 1, 2007;
92(6):
771 - 777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Strobel, N. Schaefer, C Renner, P Veit-Haibach, D Husarik, A. Koma, and T. Hany
Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients?
Ann. Onc.,
April 1, 2007;
18(4):
658 - 664.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Juweid, S. Stroobants, O. S. Hoekstra, F. M. Mottaghy, M. Dietlein, A. Guermazi, G. A. Wiseman, L. Kostakoglu, K. Scheidhauer, A. Buck, et al.
Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
J. Clin. Oncol.,
February 10, 2007;
25(5):
571 - 578.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, B. Coiffier, R. I. Fisher, A. Hagenbeek, E. Zucca, et al.
Revised Response Criteria for Malignant Lymphoma
J. Clin. Oncol.,
February 10, 2007;
25(5):
579 - 586.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Blodgett, C. C. Meltzer, and D. W. Townsend
PET/CT: Form and Function
Radiology,
February 1, 2007;
242(2):
360 - 385.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. L. Kasamon, R. J. Jones, and R. L. Wahl
Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma
J. Nucl. Med.,
January 1, 2007;
48(1_suppl):
19S - 27S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Buck, M. Bommer, S. Stilgenbauer, M. Juweid, G. Glatting, H. Schirrmeister, T. Mattfeldt, D. Tepsic, D. Bunjes, F. M. Mottaghy, et al.
Molecular Imaging of Proliferation in Malignant Lymphoma.
Cancer Res.,
November 15, 2006;
66(22):
11055 - 11061.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Guadagnolo, R. S. Punglia, K. M. Kuntz, P. M. Mauch, and A. K. Ng
Cost-Effectiveness Analysis of Computerized Tomography in the Routine Follow-Up of Patients After Primary Treatment for Hodgkin's Disease
J. Clin. Oncol.,
September 1, 2006;
24(25):
4116 - 4122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Blake, A. Singh, B. N. Setty, J. Slattery, M. Kalra, M. M. Maher, D. V. Sahani, A. J. Fischman, and P. R. Mueller
Pearls and Pitfalls in Interpretation of Abdominal and Pelvic PET-CT
RadioGraphics,
September 1, 2006;
26(5):
1335 - 1353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Guermazi and M E Juweid
PET poised to alter the current paradigm for response assessment of non-Hodgkin's lymphoma
Br. J. Radiol.,
May 1, 2006;
79(941):
365 - 367.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Juweid and B. D. Cheson
Positron-Emission Tomography and Assessment of Cancer Therapy
N. Engl. J. Med.,
February 2, 2006;
354(5):
496 - 507.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Raanani, Y. Shasha, C. Perry, U. Metser, E. Naparstek, S. Apter, A. Nagler, A. Polliack, I. Ben-Bassat, and E. Even-Sapir
Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?
Ann. Onc.,
January 1, 2006;
17(1):
117 - 122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Savage, N. Al-Rajhi, N. Voss, C. Paltiel, R. Klasa, R. D. Gascoyne, and J. M. Connors
Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience
Ann. Onc.,
January 1, 2006;
17(1):
123 - 130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Juweid
Utility of Positron Emission Tomography (PET) Scanning in Managing Patients with Hodgkin Lymphoma
Hematology,
January 1, 2006;
2006(1):
259 - 265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tatsumi, C. Cohade, Y. Nakamoto, E. K. Fishman, and R. L. Wahl
Direct Comparison of FDG PET and CT Findings in Patients with Lymphoma: Initial Experience
Radiology,
December 1, 2005;
237(3):
1038 - 1045.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W A Weber
PET for response assessment in oncology: radiotherapy and chemotherapy
Br. J. Radiol.,
November 1, 2005;
Supplement_28(1):
42 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Reinhardt, C. Herkel, C. Altehoefer, J. Finke, and E. Moser
Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
Ann. Onc.,
September 1, 2005;
16(9):
1524 - 1529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Haioun, E. Itti, A. Rahmouni, P. Brice, J.-D. Rain, K. Belhadj, P. Gaulard, L. Garderet, E. Lepage, F. Reyes, et al.
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome
Blood,
August 15, 2005;
106(4):
1376 - 1381.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Juweid, G. A. Wiseman, J. M. Vose, J. M. Ritchie, Y. Menda, J. E. Wooldridge, F. M. Mottaghy, E. M. Rohren, N. M. Blumstein, A. Stolpen, et al.
Response Assessment of Aggressive Non-Hodgkin's Lymphoma by Integrated International Workshop Criteria and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography
J. Clin. Oncol.,
July 20, 2005;
23(21):
4652 - 4661.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Schoder, A. Noy, M. Gonen, L. Weng, D. Green, Y. E. Erdi, S. M. Larson, and H. W.D. Yeung
Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
July 20, 2005;
23(21):
4643 - 4651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Juweid and B. D. Cheson
Role of Positron Emission Tomography in Lymphoma
J. Clin. Oncol.,
July 20, 2005;
23(21):
4577 - 4580.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Clin. Cancer Res.,
April 15, 2005;
11(8):
2785 - 2808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Mengiardi, H. Honegger, J. Hodler, U. G. Exner, M. D. Csherhati, and W. Bruhlmann
Primary Lymphoma of Bone: MRI and CT Characteristics During and After Successful Treatment
Am. J. Roentgenol.,
January 1, 2005;
184(1):
185 - 192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kazama, S. C. Faria, V. Varavithya, S. Phongkitkarun, H. Ito, and H. A. Macapinlac
FDG PET in the Evaluation of Treatment for Lymphoma: Clinical Usefulness and Pitfalls
RadioGraphics,
January 1, 2005;
25(1):
191 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Munker, J. Glass, L. K. Griffeth, T. Sattar, R. Zamani, M. Heldmann, R. Shi, and D. L. Lilien
Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease
Ann. Onc.,
November 1, 2004;
15(11):
1699 - 1704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. G. Schaefer, T. F. Hany, C. Taverna, B. Seifert, K. D. M. Stumpe, G. K. von Schulthess, and G. W. Goerres
Non-Hodgkin Lymphoma and Hodgkin Disease: Coregistered FDG PET and CT at Staging and Restaging--Do We Need Contrast-enhanced CT?
Radiology,
September 1, 2004;
232(3):
823 - 829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
